Eli Lilly to Acquire AtaiBeckley in $2.8B Transaction

LLY agreed to acquire AtaiBeckley in a deal announced July 16 that values the psychedelic-medicine developer at up to $3.8 billion: $2.8 billion upfront at $6.75 per share in cash, plus up to $1 billion in contingent value rights ($2.50 per share) tied to development and regulatory milestones. The cash offer represents roughly a 40% premium to AtaiBeckley's 30-day volume-weighted average price.

The acquisition marks Lilly's first move into psychedelics and centers on AtaiBeckley's lead asset BPL-003, an intranasal 5-MeO-DMT candidate for treatment-resistant depression that holds FDA Breakthrough Therapy Designation and is in Phase 3 preparation. It follows AbbVie's recent psychedelic tie-up and signals large-cap pharma's growing appetite for the category.

Shares of GH Research, a peer developing its own 5-MeO-DMT program, rose about 11% on the read-through. For LLY, the deal is a comparatively small bolt-on against its obesity and diabetes franchise, so the market's focus will center on clinical execution and the regulatory path for a still-unproven treatment class.

Related Stocks

• GH